VG H&N course intro Florence 2016.pptx

Loco regional control and p16

‐

St. I-II p16+ 90%

St. III-IV p16+

St. III-IV p16-

St I II

p16 57%

. -

DAHANCA 2000‐2013, curative intent RT, oropharynx patients with known p16 status (n=1163)